In particular, GLP-1R agonism not only emerged as a powerful tool in the treatment of T2D and excess adiposity but also displayed favorable effects on the cardiovascular system and neurodegenerative diseases. Research and development of GLP-1R agonists single receptor interventions Despite its substantial in vitro and in vivo benefits, native GLP-1s use in pharmacological interventions was hampered by its extremely limited half-life (~2-3 min), with studies estimating that even in sustained administration, only 10% of active GLP-1 enters general circulation, and even less reaches its target organ the brain
The FDA approved liraglutide (Victoza) at doses of 0.6 mg, 1.2 mg, and 1.8 mg daily for T2DM patients with unsatisfactory diet or exercise control, and 2.4 mg and 3 mg as a chronic weight management drug
With rapid weight loss, that support structure can change faster than the skin can respond
Were seeing an explosion of compound pharmacies creating compounds that are the same main ingredients as Ozempic, Mounjaro, etc. The FDA has, however, warned patients against using compounded versions of GLP-1 drugs, as they can be less effective and unsafe
The drug creates a positive feedback loop where weight loss improves the metabolic environment, which makes further metabolic normalization easier
The review also notes that GLP-1 medicines reduce complications in conditions such as obstructive sleep apnea (OSA), expanding their cardiometabolic relevance
